Kymera Therapeutics

Kymera Therapeutics to Present Preclinical Data on its First-in-Class Selective and Potent Oral IRAK4 Degraders in Cutaneous Inflammation

Company names first inflammation/immunology disease indication: Hidradenitis suppurativa Cambridge, Mass. (February 5, 2020) – Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to discover breakthrough medicines for patients, today announced the company will